CollPlant Biotechnologies Ltd.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $515.0K | $11.0M | $299.0K | $15.6M | $6.1M | $2.3M | $5.0M |
| Cost of Revenue | $835.0K | $1.6M | $2.0M | $400.0K | $2.0M | $3.0M | $1.9M | $1.7M |
| Gross Profit | $1.5M | $-1.1M | $9.0M | $-101.0K | $13.6M | $3.1M | $439.0K | $3.4M |
| Gross Margin | 64.8% | -215.5% | 81.8% | -33.8% | 87.2% | 51.1% | 18.9% | 66.9% |
| Operating Expenses | ||||||||
| Research & Development | $8.2M | $10.5M | $10.5M | $10.3M | $7.6M | $4.1M | $4.4M | $3.9M |
| SG&A Expense | $4.8M | $5.6M | $6.0M | $6.7M | $5.9M | $4.7M | $3.7M | $3.7M |
| Operating Income | $-11.5M | $-17.3M | $-7.5M | $-17.1M | $65.0K | $-5.6M | $-7.6M | $-4.2M |
| Operating Margin | -484.3% | -3,349.7% | -68.5% | -5,718.1% | 0.4% | -91.2% | -329.2% | -84.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $46.0M | $60.0M | — | — | — | — | — |
| Net Income | $-11.5M | $-16.6M | $-7.0M | $-16.9M | $237.0K | $-5.8M | $-11.2M | $-6.2M |
| Net Margin | -484.6% | -3,225.0% | -64.0% | -5,660.5% | 1.5% | -94.1% | -481.6% | -124.6% |
| EPS (Basic) | $-0.94 | $-1.45 | $-0.62 | $-1.53 | $0.02 | $-0.84 | $-2.23 | $1.43 |
| EPS (Diluted) | $-0.94 | $-1.45 | $-0.62 | $-1.53 | $0.02 | $-0.84 | $-2.23 | $1.43 |
| Shares Outstanding (Basic) | 12.2M | 11.5M | 11.4M | 11.0M | 10.0M | 6.9M | 5.0M | 190.7M |
| Shares Outstanding (Diluted) | 12.2M | 11.5M | 11.4M | 11.0M | 12.0M | 6.9M | 5.0M | 190.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |